Patents Assigned to Apotex Technologies Inc.
-
Patent number: 9550733Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Friedreich's ataxia.Type: GrantFiled: June 10, 2015Date of Patent: January 24, 2017Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
-
Patent number: 9073865Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.Type: GrantFiled: July 5, 2010Date of Patent: July 7, 2015Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'Zemba, Jolanta Maria Wodzinska, Maryna Premyslova
-
Patent number: 8735602Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D-tryptophan organic ammonium salts (1:1).Type: GrantFiled: March 19, 2012Date of Patent: May 27, 2014Assignee: Apotex Technologies inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Patent number: 8703156Abstract: An oral pharmaceutical liquid formulation comprising deferiprone and a taste masking composition, said taste masking composition comprising an effective amount of a sweetener (such as sucralose) per liter of liquid composition, an effective amount of a thickening and suspension aid, (for example hydroxyethylcellulose), per liter of liquid composition, an effective amount of a humectant (such as glycerin) per liter of liquid composition, and an effective amount of at least one flavoring agent, wherein a final form of said taste-masked pharmaceutical has a substantially non-bitter and palatable taste.Type: GrantFiled: April 25, 2008Date of Patent: April 22, 2014Assignee: Apotex Technologies Inc.Inventors: Michael Spino, Anita Hui, Cihua Yang, Mohammed N. Kabir
-
Patent number: 8673943Abstract: The present invention relates to novel derivatives of deferiprone. In particular, the present invention relates to fluorinated derivatives of deferiprone or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, processes for the manufacture thereof and their use in the treatment of neurodegenerative diseases caused by the presence of free iron or iron accumulation in neural tissues and in diseases wherein excess iron must be removed or redistributed.Type: GrantFiled: September 26, 2011Date of Patent: March 18, 2014Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao
-
Patent number: 8664262Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: GrantFiled: June 7, 2012Date of Patent: March 4, 2014Assignee: Apotex Technologies inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Patent number: 8592607Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: GrantFiled: June 7, 2012Date of Patent: November 26, 2013Assignee: Apotex Technologies inc.Inventors: Tim Fat Tam, Blaise N′Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Patent number: 8507449Abstract: A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.Type: GrantFiled: February 20, 2012Date of Patent: August 13, 2013Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Patent number: 8481588Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: GrantFiled: June 7, 2012Date of Patent: July 9, 2013Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Patent number: 8476235Abstract: A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.Type: GrantFiled: February 20, 2012Date of Patent: July 2, 2013Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Publication number: 20130072692Abstract: The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D-tryptophan organic ammonium salts (1:1).Type: ApplicationFiled: March 19, 2012Publication date: March 21, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Publication number: 20130059791Abstract: A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.Type: ApplicationFiled: February 20, 2012Publication date: March 7, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
-
Publication number: 20130060048Abstract: A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.Type: ApplicationFiled: February 20, 2012Publication date: March 7, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
-
Publication number: 20130045929Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: ApplicationFiled: June 7, 2012Publication date: February 21, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
-
Publication number: 20130045930Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: ApplicationFiled: June 7, 2012Publication date: February 21, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
-
Publication number: 20130023569Abstract: There is provided use of orally available or topically applied deferiprone for prevention of iron-induced eye damage. The use may be for preparation of a medicament or in a method of preventing iron-induced eye damage to an eye of a subject at risk for iron-induced eye damage, the method comprising administering a prophylactically effective amount of deferiprone to the subject. There is also provided the use of deferiprone for treatment of iron-related eye disorders. The use may be for preparation of a medicament or in a method of treatment of damage to an eye of a having eye damage associated with iron, the method comprising topically administering a therapeutically effective amount of deferiprone to the subject.Type: ApplicationFiled: November 12, 2009Publication date: January 24, 2013Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, APOTEX TECHNOLOGIES INC.Inventors: Michael Spino, Joshua Lawrence Dunaief
-
Publication number: 20130005987Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: ApplicationFiled: June 7, 2012Publication date: January 3, 2013Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Blaise N'ZEMBA, Regis LEUNG-TOUNG, Yingsheng WANG, Yanqing ZHAO, Lily YU
-
Publication number: 20120270882Abstract: Provided are compounds of Formula I which are derivatives of 3-Hydroxypyridin-4-ones. The compounds may be used in treatment of a medical condition related to a toxic concentration of iron. The compounds may be used for preparation of a medicament for treatment of a medical condition related to a toxic concentration of iron. The medical condition related to a toxic concentration of iron may be selected from the group consisting of: cancer, pulmonary disease, progressive kidney disease and Frederich's Ataxia.Type: ApplicationFiled: July 5, 2010Publication date: October 25, 2012Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat Tam, Regis Leung-Toung, Yingsheng Wang, Yangqing Zhao, Tao Xin, Birenkumar Shah, Blaise N'zemba, Jolanta Maria Wodzinska, Maryna Premyslova
-
Patent number: 8207217Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic form I), and the crystal modification 3 (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: GrantFiled: February 11, 2008Date of Patent: June 26, 2012Assignee: Apotex Technologies IncInventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Publication number: 20120157387Abstract: Provided are compounds which are prodrugs of D-gamma-glutamyl-D-tryptophan, methods of making the compounds and methods for using the compounds.Type: ApplicationFiled: February 20, 2012Publication date: June 21, 2012Applicant: APOTEX TECHNOLOGIES INC.Inventors: Tim Fat TAM, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Tao Xin, Wanren Li, Jolanta Maria Wodzinska, Vrajlal S. Rabadia, Birenkumar Shah, Christopher John Feeney